Perspectives in Clinical Nephrology

Kidney International (1997) 51, 2–15; doi:10.1038/ki.1997.2

Understanding the nature of renal disease progression

Giuseppe Remuzzi1, Piero Ruggenenti1 and Ariela Benigni1

1Mario Negri Institute for Pharmacological Research, and Ospedali Riunitidi Bergamo, Bergamo, Italy

Correspondence: Dr Giuseppe Remuzzi, "Mario Negri" Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy.

Received 1 February 1996; Revised 3 July 1996; Accepted 8 July 1996.

Top

References

  1. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652–659, 1982 | PubMed | ISI | ChemPort |
  2. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 241:F85–F93, 1981 | PubMed | ISI | ChemPort |
  3. Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 318:1657–1666, 1988 | PubMed | ISI | ChemPort |
  4. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384–394, 1990 | PubMed | ISI | ChemPort |
  5. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612–619, 1985 | PubMed | ISI | ChemPort |
  6. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HR, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925–1930, 1986 | PubMed | ISI | ChemPort |
  7. Anderson S, Rennke HG, Garcia DL, Brenner BM: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526–536, 1989 | PubMed | ISI | ChemPort |
  8. Hostetter TH, Meyer TW, Rennke HG, Brenner BM: Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int 30:509–517, 1986 | PubMed | ISI | ChemPort |
  9. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993–2000, 1986 | PubMed | ISI | ChemPort |
  10. Meyer TW, Anderson S, Rennke HG, Brenner BM: Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31:752–759, 1987 | PubMed | ISI | ChemPort |
  11. Eddy AA, McCulloch L, Liu E, Adams J: A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 138:1111–1123, 1991 | PubMed | ISI | ChemPort |
  12. Mori H, Yamashita H, Nakanishi C, Koizumi K, Makino S, Kishimoto Y, Hayashi Y: Proteinuria induced by transplantable rat pituitary tumor MtT SA5. Model for homologous protein overload proteinuria. Lab Invest 54:636–644, 1986 | PubMed |
  13. Magil AB: Tubulointerstitial lesions in human membranous glomerulonephritis: Relationship to proteinuria. Am J Kidney Dis 25:375–379, 1995 | PubMed | ISI | ChemPort |
  14. Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G: Tubulointerstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 30:488–496, 1986 | PubMed | ISI | ChemPort |
  15. Remuzzi G: Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 4:339–342, 1995 | PubMed | ChemPort |
  16. Apperloo AJ, De Zeeuw D, De Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45(Suppl 45):S174–S178, 1994 | ISI | ChemPort |
  17. Deen WM, Bridges CR, Brenner BM, Myers BD: Heteroporous model of glomerular size selectivity: Application to normal and nephrotic humans. Am J Physiol 249:F374–F389, 1985 | PubMed | ISI | ChemPort |
  18. Remuzzi A, Battaglia C, Rossi L, Zoja C, Remuzzi G: Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. Am J Physiol 253:F318–F327, 1987 | PubMed | ISI | ChemPort |
  19. Myers BD, Nelson RG, Williams GW, Bennett PH, Hardy SA, Berg RL, Loon N, Knowler WC, Mitch WE: Glomerular function in Pima Indians with noninsulin-dependent diabetes mellitus of recent onset. J Clin Invest 88:524–530, 1991 | PubMed | ISI | ChemPort |
  20. Myers BD, Guasch A: Mechanisms of massive proteinuria. J Nephrol 7:254–260, 1994
  21. Remuzzi A: Mathematical description of transport of water and macromolecules through the glomerular capillary wall. Curr Opin Nephrol Hypertens 4:343–348, 1995 | PubMed | ChemPort |
  22. Yoshioka T, Mitarai T, Kon V, Deen WM, Rennke HG, Ichikawa I: Role for angiotensin II in an overt functional proteinuria. Kidney Int 30:538–545, 1986 | PubMed | ISI | ChemPort |
  23. Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I: Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: A study in early passive Heymann nephritis. Circ Res 61:531–538, 1987 | PubMed | ISI | ChemPort |
  24. Lee LK, Meyer TW, Pollock AS, Lovett DH: Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 96:953–964, 1995 | PubMed | ISI | ChemPort |
  25. Iordache BE, Imberti O, Foglieni C, Remuzzi G, Bertani T, Remuzzi A: Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF/Ztm rats. J Am Soc Nephrol 5:1378–1384, 1994
  26. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 5:1492–1497, 1995 | PubMed | ISI | ChemPort |
  27. Ruiz-Ortega M, Gonzalez S, Seron D, Condom E, Bustos C, Largo R, Gonzalez E, Ortiz A, Egido J: ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 48:1778–1791, 1995 | PubMed | ChemPort |
  28. Morelli E, Loon N, Meyer T, Peters W, Myers BD: Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 39:76–82, 1990 | PubMed | ISI | ChemPort |
  29. Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G, Remuzzi G: Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 6:36–43, 1993
  30. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G: Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 39:1267–1273, 1991 | PubMed | ISI | ChemPort |
  31. Cameron JS: Clinicopathologic correlations in glomerular disease, in Kidney Disease—Present Status, edited by Sommer W, Baltimore, Williams & Wilkins, 1979, pp 76
  32. Velosa JA, Holley KE, Torres VE, Offord KP: Significance of proteinuria on the outcome of renal function in patients with focal glomerulosclerosis. Mayo Clin Proc 58:568–577, 1983 | PubMed | ISI | ChemPort |
  33. Mallick NP, Short CD, Hunt LP: HOW far since Ellis? Nephron 46:113–124, 1987 | PubMed | ISI | ChemPort |
  34. Wehrmann M, Bohle A, Bogenschutz O, Eissele R, Freislederer A, Ohlschlegel C, Schumm G, Batz C, Gartner H-V: Long-term prognosis of chronic idiopathic membranous glomerulonephritis. Clin Nephrol 31:67–76, 1989 | PubMed | ISI | ChemPort |
  35. Risdon RA, Sloper JC, De Wardener HE: Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet II:363–366, 1968
  36. Schainuck LI, Striker GE, Cutler RE, Benditt EP: Structural-functional correlations in renal disease II. The correlations. Hum Pathol 1:631–641, 1970 | Article | PubMed | ChemPort |
  37. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10:213–218, 1978 | PubMed | ISI | ChemPort |
  38. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J: Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 74:175–192, 1983 | Article | PubMed | ISI | ChemPort |
  39. Rossing P, Hommel E, Smidt UM, Parving H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715–719, 1993 | PubMed | ISI | ChemPort |
  40. Watkins PJ, Blainey JD, Brewer DB, Fitzgerald MG, Malins JM, O'sullivan DJ, Pinto JA: The natural history of diabetic renal disease. Q J Med 41:437–456, 1972 | PubMed | ISI | ChemPort |
  41. Gall M-A, Nielsen FS, Smidt UM, Parving H-H: The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. (abstract) Diabetologia 35(Suppl 1):A147, 1992
  42. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 45(Suppl 45):S150–S155, 1994 | ISI | ChemPort |
  43. Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA, Rodicio JL: Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 8:525–531, 1990 | PubMed |
  44. Gruppo Italiano Studi Epidemiologici in Nefrologia (Gisen): A long term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol 3:193–202, 1991
  45. Ruggenenti P, Perna A, Lanzoni M, Viganò GL, Remuzzi G: In non diabetic chronic nephropathies urinary protein excretion rate segregates subgroups of patients with predictably different rates of GFR decline (DGFR) (abstract). J Am Soc Nephrol 6:401, 1995
  46. Schwegler JS, Heppelmann B, Mildenberger S, Silbernagl S: Receptor-mediated endocytosis of albumin in cultured opossum kidney cells: A model for proximal tubular protein reabsorption. Pflügers Arch 418:383–392, 1991 | Article | PubMed | ISI | ChemPort |
  47. Wall DA, Maack T: Endocytic uptake, transport, and catabolism of proteins by epithelial cells. Am J Physiol 248:C12–C20, 1985 | PubMed |
  48. Maack T: Changes in the activity of acid hydrolases during renal reabsorption of lysozyme. J Cell Biol 35:268–273, 1967
  49. Maack T, Park CH, Camargo MJF: Renal filtration, transport, and metabolism of proteins, in The Kidney: Physiology and Pathophysiology, edited by Seldin DW, GIEBISCH G, New York, Raven Press, 1985, pp 1773–1803
  50. Zager RA, Schimpf BA, Bredl CR, Gmur DJ: Inorganic iron effects on in vitro hypoxic proximal tubular cell injury. J Clin Invest 91:702–708, 1993 | PubMed | ChemPort |
  51. Harris DCH, Chen L, Tay C, Chen J, Nankivell BJ: Cytotoxicity of reabsorbed protein in proximal tubule (PT) by peroxidation. (abstract) J Am Soc Nephrol 5:944, 1994
  52. Alfrey AC, Froment DH, Hammond WS: Role of iron in tubulointerstitial injury in nephrotoxic serum nephritis. Kidney Int 36:753–759, 1989 | PubMed | ISI | ChemPort |
  53. Howard RL, Buddington B, Alfrey AC: Urinary albumin excretion, transferrin and iron excretion in diabetic patients. Kidney Int 40:923–926, 1991 | PubMed | ISI | ChemPort |
  54. Olbricht CJ, Cannon JK, Garg LC, Tisher CC: Activities of cathepsin B and L in isolated nephron segments from proteinuric and non proteinuric rats. Am J Physiol 250:F1055–F1062, 1986
  55. Feld S, Hirschberg R, Artishevsky A, Nast C, Adler S: Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int 48:45–51, 1995 | PubMed | ISI | ChemPort |
  56. Baxter R, Martin J: Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: Determination by reconstitution and affinity-labeling. Proc Natl Acad Sci USA 86:6898–6902, 1989 | PubMed | ChemPort |
  57. Frystyk J, Skjaerbaek C, Dinesen B, Orskov H: Free insulin like growth factor (IGF-I and IGF-II) in human serum. FEBS Lett 348:185–191, 1994 | Article | PubMed | ISI | ChemPort |
  58. Hirschberg R: Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions. J Clin Invest (in press)
  59. Hirschberg R, Ding H, Wanner C: Effects of insulin-like growth factor I on phosphate transport in cultured proximal tubule cells. J Lab Clin Med 126:428–434, 1995 | PubMed | ChemPort |
  60. Hammerman MR, Rogers S: Distribution of IGF receptors in the plasma membrane of proximal tubular cells. Am J Physiol 253:F841–F847, 1987 | PubMed | ChemPort |
  61. Haverty TP, Kelly CJ, Hines WH, Amenta PS, Watanabe M, Harper RA, Kefalides NA, Neilson EG: Characterization of a renal tubular epithelial cell line which secretes the autologous target antigen of autoimmune experimental interstitial nephritis. J Cell Biol 107:1359–1368, 1988 | Article | PubMed | ISI | ChemPort |
  62. Ziyadeh F, Jin Y, Guo J, Ericksen M, Sharma K: Up-regulation of type II TGF-beta receptor mRNA by IGF-1 in proximal tubular cells: Role in diabetic renal hypertrophy. (abstract) J Am Soc Nephrol 6:1053, 1995
  63. Harris DCH, Chen J: Monocyte chemoattractant protein-1 (MCP-1) mRNA expression in response to protein in rat proximal tubule cells in culture. (abstract) J Am Soc Nephrol 6:1015, 1995
  64. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K: Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 9:617–648, 1991 | Article | PubMed | ISI | ChemPort |
  65. Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ: Purification and amino acid analysis of two human monocyte chemoattractants produced by pythohemagglutin-stimulated human blood mononuclear leukocytes. J Immunol 142:1956–1962, 1989 | PubMed | ISI | ChemPort |
  66. Prodjosudjadi W, Gerritsma JSJ, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, Van Es LA: Production and cytokinemediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48:1477–1486, 1995 | PubMed | ISI | ChemPort |
  67. Leonard EJ, Yoshimura T: Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11:97–101, 1990 | Article | PubMed | ISI | ChemPort |
  68. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA: Monocyte chemoattractant protein-1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 91:3652–3656, 1994 | Article | PubMed | ChemPort |
  69. Eddy AA: Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 135:719–733, 1989 | PubMed | ISI | ChemPort |
  70. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273–1287, 1994 | PubMed | ISI | ChemPort |
  71. Rovin BH, Dickerson JA, Tan LC, Hebert CA: Activation of nuclear factor-kappaB correlates with MCP-1 expression by human mesangial cells. Kidney Int 48:1263–1271, 1995 | PubMed | ISI | ChemPort |
  72. Kakizaki Y, Sugimoto K, Waga S, Tanaka H, Yokoyama M: Transcription factors NF-kappaB and AP-1 regulate gene expression of monocyte chemoattractant protein-1 (MCP-1) by bovine glomerular endothelial cells (GEN). (abstract) J Am Soc Nephrol 6:833, 1995
  73. Beg AA, Finco TS, Nantermet PV, Baldwin AS JR: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of IkappaBa: A mechanism for NF-kappaB activation. Mol Cell Biol 13:3301–3310, 1993 | PubMed | ISI | ChemPort |
  74. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U: Mutual regulation of the transcriptional activator NF-kappaB and its inhibitor, IkappaB-a. Proc Natl Acad Sci USA 90:2532–2536, 1993 | Article | PubMed | ChemPort |
  75. Pahl HL, Baeuerle PA: A novel signal transduction pathway from the endoplasmic reticulum to the nucleus is mediated by transcription factor NF-KkappaB. EMBO J 14:2580–2588, 1995 | PubMed | ISI | ChemPort |
  76. Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47:1546–1557, 1995 | PubMed | ISI | ChemPort |
  77. Butler WT: The nature and significance of osteopontin. Connect Tissue Res 23:123–136, 1989 | PubMed | ISI | ChemPort |
  78. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, Schwartz SM, Johnson RJ: Tubulointerstitial disease in glomerulonephritis: Potential role of osteopontin (uropontin). Am J Pathol 144:915–926, 1994 | PubMed | ISI | ChemPort |
  79. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers C, Schwartz S, Johnson RJ: Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 45:515–524, 1994 | PubMed | ISI | ChemPort |
  80. Main IW, Nikolic-Paterson DJ, Atkins RC: T cells and macrophages and their role in renal injury. Semin Nephrol 12:395–407, 1992 | PubMed | ISI | ChemPort |
  81. Danoff TM, Lalley PA, Chang YS, Heeger PS, Neilson EG: Cloning, genomic organization, and chromosomal localization of the Scya5 gene encoding the murine chemokine RANTES. J Immunol 152:1182–1189, 1994 | PubMed | ISI | ChemPort |
  82. Heeger P, Wolf G, Meyers C, Sun MJ, O'farrell SC, Krensky AM, Neilson EG: Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes. Kidney Int 41:220–225, 1992 | PubMed | ISI | ChemPort |
  83. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T: The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86:2863–2867, 1989 | Article | PubMed | ChemPort |
  84. Benigni A, Remuzzi G: Endothelin in the progressive renal disease of glomerulopathies. Miner Electrol Metab 21:283–291, 1995
  85. Yoshimura A, Iwasaki S, Inui K, Ideura T, Koshikawa S, Yanagisawa M, Masaki T: Endothelin-1 and endothelin B type receptor are induced in mesangial proliferative nephritis in the rat. Kidney Int 48:1290–1297, 1995 | PubMed | ISI | ChemPort |
  86. Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Modulation of glomerular endothelin and endothelin receptor gene expression in aminonucleoside-induced nephrosis. J Am Soc Nephrol 5:1585–1590, 1995 | PubMed | ISI | ChemPort |
  87. Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Renal expression of mRNAs for endothelin-1. endothelin-3 and endothelin receptors in NZB/W F1 mice. Renal Physiol Biochem 16:233–243, 1993 | PubMed |
  88. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 44:895–899, 1995 | PubMed | ISI | ChemPort |
  89. Lee M-E, Temizer DH, Clifford JA, Quertermous T: Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells. J Biol Chem 266:16188–16192, 1991 | PubMed | ISI | ChemPort |
  90. Dorfman DM, Wilson DB, Bruns G, Orkin SH: Human transcription factor GATA-2. J Biol Chem 267:1279–1285, 1992 | PubMed | ISI | ChemPort |
  91. Marsen TA, Schramek H, Dunn MJ: Renal actions of endothelin: Linking cellular signaling pathways to kidney disease. Kidney Int 45:336–344, 1994 | PubMed | ISI | ChemPort |
  92. Lee M-E, Dhadly MS, Temizer DH, Clifford JA, Yoshizumi M, Quertermous T: Regulation of endothelin-1 gene expression by fos and Jun. J Biol Chem 266:19034–19039, 1991 | PubMed | ISI | ChemPort |
  93. Kohan DE: Endothelin synthesis by rat tubule cells. Am J Physiol 261:F221–F226, 1991 | PubMed | ChemPort |
  94. Kohan DE, Padilla E: Endothelin-1 is an autocrine factor in rat inner medullary collecting ducts. Am J Physiol 32:F607–F612, 1992
  95. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco PM, Remuzzi G: Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 26:934–941, 1995 | PubMed | ISI | ChemPort |
  96. Ong ACM, Jowett TP, Firth JD, Burton S, Kitamura M, Fine LG: A new paracrine loop implicated in human tubulo-interstitial fibrosis: Tubular-derived endothelins modulate renal interstitial fibroblast function. (abstract) J Am Soc Nephrol 4:473, 1993
  97. Chen XM, Yu LF, Zeng Q: Production of endothelin (ET-1) in kidney tubular cell (LLC-PK1) induced by extracellular matrix (ECM). ISN XIII Congress, Madrid, July 2–6, Theme VII, 1995, p 299 (abstract)
  98. Achmad T, Rao G: Chemotaxis of human blood monocytes towards endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 189:994–1000, 1992 | PubMed |
  99. Helset E, Sildnes T, Seuelid R, Konopski ZS: Endothelin-1 stimulates human monocytes in vitro to release TNF-alpha, IL-1beta and IL-6. Mediators of Inflammation 2:417–422, 1993
  100. Orisio S, Benigni A, Bruzzi I, Corna D, Perico N, Zoja C, Benatti L, Remuzzi G: Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 43:354–358, 1993 | PubMed | ISI | ChemPort |
  101. Zoja C, Corna D, Bruzzi I, Foglieni C, Bertani T, Remuzzi G, Benigni A: Passive Heymann nephritis: Evidence that angiotensin converting enzyme inhibition reduces proteinuria and retards renal structural injury. Exp Nephrol 4:213–221, 1996 | PubMed | ISI | ChemPort |
  102. Theuring F, Schmager F, Thone-Reinicke C, Chotzen S, Quertermous T, Schleuning W-D, Hocher B: Transgenic mice in endothelin research. Fourth International Conference on Endothelin, London, April 23–26, 1995, p 146 (abstract)
  103. Hocher B, Liefeldt L, Thöne-Reineke C, Orzechowski H, Distler A, Bauer C, Paul M: Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 28:196–201, 1996 | PubMed | ISI | ChemPort |
  104. Takeda M, Komeyama T, Tsutsui T, Mizusawa T, Katayama Y, Go H, Tamaki M, Hatano A: Changes in urinary excretion of endothelin-1-like immunoreactivity before and after unilateral nephrectomy in humans. Nephron 67:180–184, 1994
  105. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, Marumo F: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 39:307–311, 1991 | PubMed | ISI | ChemPort |
  106. Murer L, Zacchello G, Basso G, Scarpa A, Montini G, Chiozza ML, Zacchello F: Immunohistochemical distribution of endothelin in biopsies of pediatric nephrotic syndrome. Am J Nephrol 14:157–161, 1994
  107. Liu X-H, Oldroyd S, Abbate M, Corna D, Zoja C, Benigni A, Remuzzi G: Combined administration of ACE inhibitor (ACEi) and angiotensin II receptor antagonist (AII ra) normalizes excessive renal endothelin (ET-1) in rats with passive Heymann nephritis. (abstract) J Am Soc Nephrol 6:874, 1995
  108. Zoja C, Corna D, Facchinetti D, Maffi R, Luzzana E, Bertani T, Remuzzi G: Combining ACE inhibition and angiotensin II (AII) receptor blocking stop renal disease progression in experimental membranous nephropathy (MN). (abstract) J Am Soc Nephrol 6:860, 1995
  109. Spector AA: Plasma albumin as a lipoprotein, in Biochemistry and Biology of Plasma Lipoproteins. Volume II: The Biochemistry of Disease, edited by Scanu AM, SPECTOR AA, New York, Marcel Dekker, 1986, pp 247–279
  110. Humes HD, Nguyen VD, Cieslinski DA, Messana JM: The role of free fatty acids in hypoxia-induced injury to renal proximal tubule cells. Am J Physiol 256:F688–F696, 1989 | PubMed | ISI | ChemPort |
  111. Gherardi E, Calandra S: Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside. Biochim Biophys Acta 710:188–196, 1981
  112. Kees-Folts D, Sadow JL, Schreiner GF: Tubular catabolism of albumin is associated with the release of an inflammatory lipid. Kidney Int 45:1697–1709, 1994 | PubMed | ChemPort |
  113. Schreiner GF: Renal toxicity of albumin and other lipoproteins. Curr Opin Nephrol Hyperten 4:369–373, 1995
  114. Rustom R, Jackson MJ, Critchley M, Bone JM: Tubular metabolism of aprotinin 99mTc and urinary ammonia: Effects of protein-uria. Miner Electrol Metab 18:108–112, 1992
  115. Nath KA, Hostetter MK, Hostetter TH: Pathophysiology of chronic tubulointerstitial disease in rats: Interactions of dietary acid load, ammonia and complement component C3. J Clin Invest 76:667–675, 1985 | PubMed | ISI | ChemPort |
  116. Jackle I, Gunther H, Von Gise H, Alt JM, Bohle A, Stolte H: Kidney function and protein excretion in relation to pathomorphology of glomerular diseases. Contrib Nephrol 68:128–135, 1988 | PubMed | ChemPort |
  117. Bohle A, Von Gise H, Mackensen-Haen S, Stark-Jakob B: The obliteration of the post-glomerular capillaries and its influence upon the function of both glomeruli and tubuli functional interpretation of morphologic findings. Klin Wochenschr 59:1043–1051, 1981 | Article | PubMed | ISI | ChemPort |
  118. Heptinstall RH: Chronic glomerulonephritis, end-stage kidney and visceral changes in chronic renal failure, in Pathology of the Kidney (3rd ed), edited by Heptinstall RH, Boston, Little, Brown and Co, 1983, pp 601–636
  119. Zamlauski-Tucker MJ, Van Liew JB, Goldinger J, Noble B: Persistent proximal tubule dysfunction late in Heymann nephritis. Kidney Int 37:1536–1542, 1990
  120. Hutchison FN, Kaysen GA: Albuminuria causes lysozymuria in rats with Heymann nephritis. Kidney Int 33:787–791, 1988
  121. Harrison JF, Lunt GS, Scott P, Blainey JD: Urinary lysozyme, ribonuclease, and low-molecular-weight protein in renal disease. Lancet I:371–375, 1968
  122. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM: Mechanisms underlying transition from acute glomerular injury late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 82:1757–1768, 1988 | PubMed | ISI | ChemPort |
  123. Diamond JR, Anderson S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Am J Pathol 137:1323–1332, 1990 | PubMed | ISI | ChemPort |
  124. Bertani T, Zoja C, Abbate M, Rossini M, Remuzzi G: Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein contents. Lab Invest 60:196–204, 1989 | PubMed | ISI | ChemPort |
  125. Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H: Long-term prognosis of focal sclerosis glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 33:115–122, 1990 | PubMed | ISI | ChemPort |
  126. Mackensen-Haen R, Eissele R, Bohle A: Contribution on the correlation between morphometric parameters gained from the renal cortex and renal function in IgA nephritis. Lab Invest 59:239–244, 1988 | PubMed |
  127. Schmitt H, Cavalcanti de Oliveira V, Bohle A: Tubulo-interstitial alterations in type I membranoproliferative glomerulonephritis. An investigation of 259 cases. Pathol Res Pract 182:6–10, 1987
  128. McDell JR, Hays RC, Guggenheim SJ, Steigerwald JC: Tubulointerstitial renal disease in systemic lupus erythematosus. Arch Mem Med 145:1996–1999, 1985
  129. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA: The pathogenesis of chronic renal failure in diabetic nephropathy: Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 187:251–259, 1991 | PubMed | ISI | ChemPort |
  130. Mackensen-Haen S, Bohle A, Christensen J, Wehrmann M, Kendziorra H, Kokot F: The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases. Clin Nephrol 37:70–77, 1992 | PubMed | ChemPort |
  131. Howie AJ, Gunson BK, Sparke J: Morphometric correlates of renal excretory function. J Pathol 160:245–253, 1990
  132. Marcussen N: Atubular glomeruli and the structural basis for chronic renal failure. Lab Invest 66:265–284, 1992 | PubMed | ISI | ChemPort |
  133. Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, Mecca G, Remuzzi G, Donati MB: Adriamycin-induced nephrotic syndrome in rats. Lab Invest 46:16–23, 1982 | PubMed | ISI | ChemPort |
  134. Nadasdy T, Silva FG, Hogg RJ: Minimal change nephrotic syndrome-focal sclerosis complex (including IgM nephropathy and diffuse mesangial hypercellularity), in Renal Pathology: With Clinical and Functional Correlations, edited by Tisher CC, BRENNER BM, Philadelphia, J.B. Lippincott Co, 1994, pp 330–389
  135. Schulze M, Donadio JV, Pruchno CJ, Baker PJ, Johnson RJ, Stahl RAK, Watkins S, Martin DC, Wurzner R, Gotze O, Couser WG: Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 40:533–538, 1991 | PubMed | ISI | ChemPort |
  136. Ogradowski JL, Herbert LA, Sedmak K, Cosio FG, Tamerius J, Kolb W: Measurement of C5b-9 in urine in patients with the nephrotic syndrome. Kidney Int 40:1141–1147, 1991 | PubMed | ISI | ChemPort |
  137. Camussi G, Tetta C, Mazzucco G, Vercellone A: The brush border of proximal tubules of normal human kidney activates the alternative pathway of the complement system in vitro. Ann NY Acad Sci 420:321–324, 1983 | PubMed | ChemPort |
  138. Olson JL, Hostetter TH, Rennke HG, Brenner BM, Venkatachalam MA: Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int 22:112–126, 1982 | PubMed | ISI | ChemPort |
  139. Wen S-F, Huang T-P, Moorthy AV: Effects of low-protein diet on experimental diabetic nephropathy in the rat. J Lab Clin Med 106:589–597, 1985
  140. Walker JD, Bending JJ, Dodds RA, Mattock MB, Murrells TJ, Keen H, Viberti GC: Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 11:1411–1415, 1989
  141. El-Nahas AM, Masters-Thomas A, Brady SA, Farrington K, Wilkinson U, Milson AJW, Varghese Z, Moorhead JF: Selective effect of low protein diets in chronic renal diseases. Br Med J 289:1337–1341, 1984
  142. Rosman JB, Ter Wee PM, Meijer S, Piers-Becht TP, Sluiter WJ, Donker AJ: Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet 2:1291–1296, 1984 | PubMed | ISI | ChemPort |
  143. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877–884, 1994 | Article | PubMed | ISI | ChemPort |
  144. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 85:541–549, 1990 | PubMed | ISI | ChemPort |
  145. Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45(Suppl 45):S145–S149, 1994 | ISI | ChemPort |
  146. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304:339–343, 1992 | ISI | ChemPort |
  147. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456–1462, 1993 | Article | PubMed | ISI | ChemPort |
  148. Breyer JA: Medical management of nephropathy in type I diabetes mellitus: Current recommendations. J Am Soc Nephrol 6:1523–1529, 1995
  149. Viberti G, Mogensen CE, Groop LC, Pauls JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271:275–279, 1994 | Article | PubMed | ISI | ChemPort |
  150. Laffel LMB, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99:497–504, 1995 | Article | PubMed | ISI | ChemPort |
  151. Bakris GL, Copley JB, Vicknair N: Blood pressure reduction and progression of diabetic nephropathy in african americans(AA): A five year follow-up. (abstract) J Am Soc Nephrol 6:446, 1995 | ISI |
  152. Bakris GL, Copley JB, Vicknair N, Leurgans S: Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM). (abstract) J Am Soc Nephrol 6:446, 1995 | ISI |
  153. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 156:286–289, 1996 | Article | PubMed | ISI | ChemPort |
  154. Apperloo AJ, De Zeeuw D, De Joug PE: The initial antiproteinuric effect of antihypertensive treatment predicts the effect of treatment on long-term renal function outcome. (abstract) J Am Soc Nephrol 3:279, 1992
  155. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL: Long term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20:240–248, 1992 | PubMed | ISI | ChemPort |
  156. Kamper AL, Straudgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423–430, 1992 | PubMed | ISI | ChemPort |
  157. Hannedouche T, Laudais P, Goldfarb B, El Esper N, Fournier A, Gadin M, Durand D, Chenard J, Mignon F, Sue JM, Griinfeld JP: Randomized controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. Br Med J 309:833–837, 1994 | ISI | ChemPort |
  158. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P, Ace Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945, 1996 | Article | PubMed | ISI | ChemPort |
  159. Gansevoort RT, Sluiter WJ, Hemmelder MH, De Zeeuw D, De Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963–1974, 1995 | PubMed | ISI | ChemPort |
  160. De Jong PE, Anderson S, De Zeeuw D: Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: Will such treatments also help to improve renal function outome? J Am Soc Nephrol 3:1333–1341, 1993 | PubMed | ChemPort |
  161. Sawicki PT: Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 13:933–938, 1995
  162. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 123:754–762, 1995 | PubMed | ISI | ChemPort |
  163. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J: Blood pressure and end-stage renal disease in men. N Engl J Med 334:13–18, 1996 | Article | PubMed | ISI | ChemPort |
  164. Iseki K, Ikemiya Y, Fukiyama K: Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int 49(Suppl 55):S69–S71, 1996
  165. Weidmann P, Schneider M, Bohlen L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant 10(Suppl 9):39–45, 1995 | PubMed | ISI |
  166. Kasiske BL, Kalil RSN, Jennie Z, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129–138, 1993 | PubMed | ISI | ChemPort |
  167. Bohlen L, De Courten M, Weidmann P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 7:84S–92S, 1994 | PubMed |
  168. Heeg JE, De Jong PE, Van der Hem GK, De Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272–279, 1989 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT